Item 2. Unregistered Sales of Equity Securities
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer purchases of equity securities for the three months ended March 31, 2025 were as follows:
ISSUER PURCHASES OF EQUITY SECURITIES
($ in millions)
Period Total Number
of Shares
Purchased (1)
Average Price
Paid Per
Share Total Number of Shares
Purchased as Part of
Publicly Announced Plans or
Programs
Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs (1)
January 1 - January 31 2,424,000 $98.65 2,424,000 $12,162
February 1 - February 28 4,182,640 $88.23 4,182,640 $11,793
March 1 - March 31 6,002,753 $92.61 6,002,753 $11,237
Total 12,609,393 $92.32 12,609,393
(1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck’s common stock for its treasury. In January 2025, the Board of Directors approved a plan to purchase up to an additional $10 billion of Merck’s common stock for its treasury.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.